

# RICH



Research Infrastructures Consortium for Horizon 2020

<http://www.rich2020.eu/>

Stefan Jungbluth, PhD MBA  
European Vaccine Initiative (EVI)

TRANSVAC – Supporting vaccines of the future



*The RICH-2 Project (GA no. 854109) is supported by DG Research and Innovation of the European Commission under the Research Infrastructures Programme of the H2020 Framework Programme.*

# TRANSVAC – An overview



# TRANSVAC – An overview



Supporting innovation and development of **human** and **veterinary, prophylactic** and **therapeutic** vaccines



Accelerating vaccine development by developing & applying cutting-edge technologies



Offering training courses to provide fundamental and advanced knowledge in vaccinology



Developing a sustainable vaccine infrastructure accelerating vaccine R&D

# TRANSVAC – An overview



Supporting innovation and development of **human** and **veterinary, prophylactic** and **therapeutic** vaccines



Accelerating vaccine development by developing & applying cutting-edge technologies



Offering training courses to provide fundamental and advanced knowledge in vaccinology



Developing a sustainable vaccine infrastructure accelerating vaccine R&D




Additional EC funding specifically for supporting development of COVID-19 vaccines!


# TRANSVAC and COVID-19


Project	Title	Institution		Country	Gender	Service providers
MUCOVAC	Development of a vaccine candidate against SARS-COV-2 via the muNS-Mi platform by production of microspheres (MS) containing three different viral antigens	CIQUS - Centre for Research in Biological Chemistry and Molecular Materials	Research Institution	ES	M	BPRC, NL/HZI, DE/EATRIS, NL
P-nCoV-Gap	Gaps in the project: Prevention of SARS-CoV-2 infection in at risk groups through development and clinical testing of a novel Virus Like Particle (VLP) vaccine.	EC project consortium	Research Institution	DK	M	SSI, DK/HZI, DE/UNISI, IT/ BPRC, NL/ EATRIS,
SPORCOVAX	Novel mucosal vaccination to covid-19 and influenza with both prophylactic and therapeutic potential	SporeGen Ltd.	SME	UK	M	HZI, DE/IRTA, SP
COROVAC-LITE	Immunogenicity of recombinant SARS-CoV-2 Spike Protein Subunits plus a novel, potent adjuvant in Non-Rodent Species; Possibilities of a Single-Low-Dose Vaccine against Coronavirus	LiteVax BV / ImmunoPrecise Antibodies Europe (IPA)	SME	NL	M	IRTA, ES
OVX-COVID	DEMONstrate the efficacy proof of concept of a T-cell based vaccine targeting Sars-COV-2 Nucleocapsid antigen with the pro-immunogenic oligoDOM® technology	Osivax	SME	FR	F	VFI, UK/CEA, FR/
AVVAX-COVID-19	Adjuvanted virosomal COVID-19 vaccine preventing virus transmission and minimizing the risk of enhanced disease.	Mymetics SA	SME	CH	M	iBET, PT/IME, DE/HZI, DE/BPRC, NL
SysImmCoV2	Host signatures predicting SARS-CoV-2 antibody responses and their association with protection	ISGlobal	Research Institution	ES	F	iBET, PT/IME, DE/HZI, DE/Bioaster, FR, LU, NL/CEA, FR/UNISI, IT
Covivax	Identification of a SARS-CoV-2 vaccine effective in ferret infection model	Takis biotech	SME	IT	M	PHE, UK




# TRANSVAC – Past, present (& future ?)

















*Etc etc....*

*~50 Partnership candidates!!*

*Not yet decided which ones will move forward...*

- Many -too many?- potential opportunities
- H Europe budget chops: too little funding for too many things?
- COVID *et al* have come to stay: shouldn't there be more money for health R&D?



# TRANSVAC

## Thank you

Find out more at [www.transvac.org](http://www.transvac.org)

Contact us:

[transvacinfo@euvaccine.eu](mailto:transvacinfo@euvaccine.eu)

[stefan.jungbluth@euvaccine.eu](mailto:stefan.jungbluth@euvaccine.eu)

Follow European Vaccine Initiative



This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement N° 730964.